Tesamorelin Peptide

A pivotal Phase 3 multicenter, double-blind, placebo-controlled trial published by Falutz and colleagues in the New England Journal of Medicine evaluated tesamorelin in 412 research subjects with HIV-associated central adiposity. This study established the foundational efficacy and pharmacodynamic profile of the compound and remains one of the most cited references in GHRH analog research.^[1]

Study Design

• Subjects: 412 HIV-positive adults with excess abdominal fat (waist circumference >95 cm men, >94 cm women; waist-to-hip ratio >0.94 men, >0.88 women)
• Duration: 26 weeks, with a 26-week extension phase
• Dosing: 2 mg subcutaneous tesamorelin daily vs. placebo (2:1 randomization)
• Primary endpoint: Percent change in visceral adipose tissue (VAT) measured by single-slice abdominal CT at L4-L5

Key Results

• VAT reduction: -15.2% in tesamorelin group vs. +5.0% in placebo (p<0.001)
• Trunk fat: -1.1 kg reduction with tesamorelin
• IGF-1: +81% increase from baseline, remaining within physiological range in >90% of subjects
• Triglycerides: -50 mg/dL reduction
• Adiponectin: +25% increase, consistent with metabolically healthier adipose remodeling
• No significant change in subcutaneous adipose tissue, demonstrating VAT selectivity
• Glucose homeostasis: no significant change in fasting glucose or HbA1c at 26 weeks

Mechanistic Insights

The trial confirmed that tesamorelin-induced GH and IGF-1 elevations remained within physiological boundaries, with no evidence of acromegalic features or supraphysiological IGF-1 excursions. Importantly, the preferential VAT loss without subcutaneous fat loss contrasts sharply with caloric restriction or general lipolytic agents, supporting the depot-selective mechanism driven by visceral adipocyte GH/IGF-1 responsiveness.

Context Versus Related Compounds

The magnitude of VAT reduction (-15.2%) exceeds what has been reported with sermorelin (GHRH 1-29) in comparable research populations, attributable to tesamorelin's DPP-IV resistance and sustained receptor occupancy. The data also distinguished tesamorelin from ghrelin mimetics such as MK-677, which produce broader fat redistribution and notable appetite stimulation. This study established VAT as a tractable, quantifiable endpoint for GHRH analog research and set the methodological standard for subsequent investigations.

Beyond visceral adipose tissue, tesamorelin has been investigated for its effects on hepatic lipid content in research models of non-alcoholic fatty liver disease (NAFLD). A landmark randomized controlled trial by Stanley and colleagues published in The Lancet HIV provided the first prospective evidence that GHRH analog stimulation can reduce hepatic triglyceride content independently of visceral fat changes.^[1]

Study Design

• Subjects: 61 HIV-positive adults with hepatic steatosis (intrahepatic triglyceride content ≥5% by proton MR spectroscopy)
• Duration: 12 months
• Dosing: 2 mg subcutaneous tesamorelin daily vs. placebo
• Endpoints: Change in hepatic fat fraction (1H-MRS), liver histology (paired biopsies in subset), NAFLD activity score (NAS)

Key Results

• Absolute hepatic fat reduction: -2.0% with tesamorelin vs. +0.9% with placebo (p=0.0006)
• Relative reduction in liver fat: -32% from baseline
• 37% of tesamorelin-treated subjects achieved resolution of steatosis (intrahepatic triglyceride <5%) vs. 4% placebo
• NAFLD activity score: significant reduction driven by improvements in steatosis and lobular inflammation subscores
• No progression of liver fibrosis observed; trend toward fibrosis stage improvement
• ALT and AST: significant decrease vs. placebo

Mechanistic Interpretation

The hepatic effects appear to involve multiple pathways: GH/IGF-1-mediated suppression of de novo lipogenesis via reduced SREBP-1c activity, enhanced hepatic fatty acid oxidation through PPAR-alpha upregulation, and improved insulin signaling at the hepatocyte level. These findings position tesamorelin as a unique research tool for studying the GH-liver axis in steatohepatitis models, distinct from agents acting through FGF21, GLP-1, or thyroid hormone receptor pathways.

Implications for Metabolic Research

This study expanded the research utility of tesamorelin beyond body composition into hepatic metabolism, suggesting that restoration of physiological GH pulsatility may have organ-specific lipolytic effects mediated by tissue-level IGF-1 production. Subsequent transcriptomic analyses of liver biopsies from this cohort identified downregulation of fibrogenic and inflammatory gene networks, providing molecular validation of the imaging findings.^[2]

A pivotal 52-week extension study published in the Journal of Acquired Immune Deficiency Syndromes evaluated the long-term safety, tolerability, and metabolic effects of tesamorelin 2 mg administered subcutaneously once daily in HIV-infected patients with excess abdominal adiposity. The trial enrolled 816 participants across two parallel Phase 3 studies, with the extension phase designed to characterize durability of visceral adipose tissue (VAT) reduction and changes in glucose homeostasis over chronic GHRH receptor stimulation.

Study Design:

• Subjects: 816 HIV-positive adults with central adiposity (waist circumference >95 cm men, >94 cm women; waist-to-hip ratio >0.94 men, >0.88 women)
• Duration: 26 weeks primary phase + 26 weeks extension (52 weeks total)
• Dosing: Tesamorelin 2 mg SC daily vs. placebo, with re-randomization at week 26
• Primary endpoints: Percent change in VAT (CT scan), IGF-1 levels, glucose parameters

Key Results:

• Sustained VAT reduction of -18.0% in continuous tesamorelin recipients vs. +2.2% in placebo (p<0.001)
• Mean IGF-1 increase of +106 ng/mL (within physiologic range for ~90% of subjects)
• Trunk fat reduced by -1.0 kg while limb fat and lean mass preserved
• Triglycerides decreased -50 mg/dL (p<0.001) and adiponectin increased significantly
• No clinically significant change in HbA1c (+0.1%) or fasting glucose at 52 weeks
• Discontinuation due to adverse events: 11% tesamorelin vs. 6% placebo, primarily injection-site reactions

Importantly, the study demonstrated that VAT reduction was rapidly reversed upon tesamorelin discontinuation, with patients switched to placebo at week 26 returning to baseline VAT by week 52. This finding established that continuous GHRH receptor stimulation is required to maintain the lipolytic effect — a pharmacodynamic property that distinguishes tesamorelin from interventions producing durable adipose remodeling.

Glucose tolerance was carefully monitored given GH's known counter-regulatory effects on insulin signaling. While transient elevations in 2-hour OGTT glucose were observed at week 26, these normalized by week 52, suggesting metabolic adaptation. This contrasts with exogenous recombinant human GH, which produces sustained insulin resistance in similar populations. The preservation of pulsatile GH secretion with tesamorelin is thought to underlie this more favorable glycemic profile.

The trial also documented preservation of bone mineral density and lean body mass, supporting the hypothesis that physiologic GHRH receptor activation produces a tissue-selective lipolytic effect rather than generalized anabolism. These findings supported the FDA approval of tesamorelin (Egrifta) for HIV-associated lipodystrophy in 2010 and remain the foundation for ongoing research into GHRH analog applications.